Introduction
Spontaneous
Cushing’s Syndrome (CS) is relatively rare disorder. The estimated incidence of
CS is 0.2-5 per million people per year and 66-70% of patients is due to Cushing’s
Disease (CD). LODST is a tool to documentation of spontaneous CS. It is
indicated for clinically suspected CS and to evaluate functional status of
adrenal incidentaloma. Suppressed cortisol value excludes spontaneous CS. But
there are at least two exceptions. One, when test is done during the silent
period in episodic variant of CD and other one is when 1 mg dexamethasone is
high dose to produce false negative in early or mild cases. There is a
continued search of more sensitive biochemical and imaging tests with a trend
of involving multidiscipline for more efficiently CS management. In this
context, we analyzed our laboratory data of LODST to reassess its’ current role
[1-22].
Method
To
assess the utility of LODST we analyzed the available data (cortisol, age and
sex) of all 154 LODST done from July 2017 to
December
2019 in Endocrinology Laboratory of Bangladesh Institute for Research and
Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM). Twenty
six percent of cases (n=40) were positive for CS. We analyzed the data between
2 groups in search of utility of this tool.
Test procedure and
interpolation of LODST: Dexamethasone 1 mg is administered orally between 11
PM and midnight. Blood is drawn for serum cortisol levels in the next morning
between 8 and 9 AM. A serum cortisol level < 50 nmol/L is considered as
suppressed meaning exclusion of spontaneous hypercortisolemia.
Assay method: We used two
machines for Cortisol assay 1. ARCHITECT Cortisol assay which is a delayed
one-step immunoassay using CMIA technology (Chemiflex) by Abbott i2000 machine.
Its detection limit of serum sample is (41.385-14484.75 nmol/L) and 2. AVIDA
Centura XP assay which is a competitive immunoassay using CMIA technology by
SIEMENS immunosystem. Its detection limit of serum sample is (0.20 -2069
nmol/L).
Data: Variable included
are cortisol, age, sex and Age group. Population is divided into suppressed and
no suppressed and groups comparison and logistic analysis to find risk
factor(s) for non- suppression. Comparison between groups for continuous
variable (cortisol) was done by independent sample t-test and for logical
variable (sex and age group) by chi square in cross table. We used IBM SPSS
statistics 20 for this purpose.
Result
Of
154 cases, 45(29.2%) were in pediatric age group (age <19 years) and rest
109 adult; and 109 (70.8%) were female & rest 45 male. By LODST complete
suppression (Cortisol < 50 nmol/L) occurred in 114 (74%) cases. So detection
rate of ODST is 26% in this study population.
Descriptive data
Cortisol
of Supressed population expressed as mean + SE
of mean; 95% CI & (range) innmol/L. For Total (n=114): 23.34 + 0.74;
(21.87-24.80) and (6.47-48.19).
·
For
male (n=33): 23.67 + 1.17; (21.28
-26.06) and (12.58 -39.83).
·
And
for female (n=81): 23.19 + 0.93;
(21.35-25.04) and (6.47- 48.19).
·
For
Adult (n=77): 24.27 + 0.89;
(22.51-26.04) and (12.20-48.19).
· And Children (n=37): 21.38 + 01.29; (18.76 – 23.99) and (6.47- 39.83) (Tables 1 and 2).
Cortisol
of Not Suppressed population expressed as mean + SE of mean; 95%CI and (range)
innmol/L.
For
Total (n=40): 292.48 + 40.15;
(211.27-373.69) and (51.06- 1049.88).
·
For
male (n=12): 286.59 + 88.03;
(92.83-480.35) and (51.27- 1025.92).
·
And
for female (n =28): 295.00 + 44.41;
(203.88 -286.13) and (51.06-1049.88).
·
For
Adult (n=32): 271.56 + 41.76;
(186.39- 356.73) and (51.06 -1025.92).
·
And
Children (n=8): 376.17 + 112.96;
(109.05 -643.28) and (53.70 -1049.88) (Tables
1 and 2).
Comparison data
In population of Suppressed cortisol (n=114) Mean Difference (MD) of cortisol between male (n=33) and female (n=81): as mean + SE of mean and (95%CI) .48+ 1.62(-3.72 – 2.77); sig. 772. And between adult (n=77) and children (n=37) 2.89+ 1.56(-.20 – 5.99) sig. 067 (Table 2). In population of Non Suppressed cortisol (n= 40) MD of cortisol between male (n12) and female (n28) as mean + SE of mean and (95%CI) 8.42 + 88.75 (-188.08 – 171.24); sig. 925 and between adult (n32) and children (n8) 104.61 + 100.26(-307.57- 89.35) sig. 303. See table 2.Therefore, there is no difference in cortisol level (sig. < .067) by age group and sex in either of the population. See table 2.MD of age between population of Supressed cortisol (n114) and Not Supressed cortisol (n40) as mean + SE of mean and (95%CI) 7.88 + 2.74 (2.46 -13.31), sig.005 (Table 1).
Logistic analysis data
Binary
logistic regression equation with age, sex & age group distribution as
covariate document that the suppressed and non- suppressed populations are
different (sig.000) and such deference is influence by their age (sig..021) but
not by sex (sig.821) or age group (sig.743) (Figures 1 and 2).
Figure 1: Cortisol levels during LODST.
Figure 2: Comparison of sex
and age group data during LODST. Therefore, advancing age is an independent risk factor
for CS.
Discussion
Like
other aspects of endocrinology, the spectrum of CS is constantly under
evolution. And it is in fact due to multidisciplinary involvement in its
management. We observed there are already some changes of frequencies of its different
symptom. This shifted the Cushing’s appearance of CS to a minimum or early
feature of hypercortisolema. This is the result of increased early delectation
of adrenal incidentaloma and they are mostly asymptomatic cases if identified
as CS. Moreover, due to involvement of neurosurgery and imaging specialist more
and more CD cases are being detected and treated. Our study documented the
detection rate of Cushing Syndrome by LODST is 26% in a mixed population of
symptomatic and or asymptomatic (adrenal incidentaloma) for CS. Considering the
availability, detection rate and cost we opine the LODST should remain as the
initial screening tool of investigation CS has it has been supported by other
studied [23-27].
The
newer, more sophisticated and sensitive tools like free cortisol in urine or
saliva, lower dose suppression test(30); CRF stimulated inferior petrosal sinus
sampling etc. should be in practice in specialized units in negative ODST
cases. An imaging at pituitary is need for all LODST negative cases. CT
scanning of the adrenal gland and MRI of the pituitary gland are performed to
detect the presence of any adrenal or pituitary adenomas or incidentalomas.
Scintigraphy of the adrenal gland with iodocholesterol scan is now may be needed
(35). Petrosal sinus sampling and ACTH assay is necessary for cases of
Cushing's disease are less than 2 mm in size and difficult to detect using MRI
or CT imaging.
Conventional
MRI (CMRI) are now being replaced by Dynamic Contrast-Enhanced MRI (DMRI) and Spoiled
Gradient–Recalled Acquisition (SPGR) which have the potentiality to increase
value of MRI for CD due to micro adenoma will increase in the days to come. When
imaging is positive but biochemical test is/are negative than we can follow a guideline
for incidentoloma. Recent trend of shifting symptomatic (Cushingoid) to
asymptomatic (minimum symptoms presentation of CS is supported by the raised
prevalence of CD. An involvement of neuroradiology and neurosurgery with
endocrinology has definite contribution in this challenging area of
endocrinology [28-36].
In
the present study we have documented age as an independent risk factor for CS
so we proposed when standard imaging and biochemical tools are negative but age
is > 30 years they need to be enrolled in follow-up protocols along with
cases clinically suspected to be in silent phase of episodic variant of CD.
Newer biochemical and imaging tests for CS/CD should be done in specialized center.
Analysis of diagnostic and outcome data together has potential to develop
simpler and cost-effective management policy for CS.
Conclusion
We opine to use LODST as the screening tool for Cushing Syndrome because of its good detection rate and availability for long time. Then all LODST negative cases should be subjected to dual diagnostic tools - imaging (the pituitary and adrenal) plus at least one newer biochemical test (UFC/ Salivary/ other). Negative cases for both the tools need to be enrolled in follow up protocols if age > 30 years or if symptoms score suggest episodic variant of CD and rest can be excluded from follow up. Positive in imaging tool but negative in biochemical tool(s) should be managed according to guideline (s) for incidentaloma (Table 3).
Note: Biochemical tools are urinary or salivary cortisol or others such as very low dose dexamethasone suppression, Inferior petrosal sinus sampling combining CRF stimulation etc. Imaging tools MRI of Pituitary (preferably newer version) or CT of adrenals etc.
References
- Steffensen C, Bak
AM, Rubeck KZ and Jørgensen JOL. Epidemiology of Cushing’s syndrome (2010)
Neuroendocrinology 1:1-5. https://doi.org/10.1159/000314297
- Lindholm J, Juul S,
Jørgensen JO, Astrup J, Bjerre P, et al. Incidence and late prognosis of
cushing’s syndrome: a population-based study (2001) J Clin Endocrinol Metab 86:
117-23. https://doi.org/10.1210/jcem.86.1.7093
- http://www.ncbi.nlm.nih.gov/books/NBK470218/
- Stratakis CA.
Cushing syndrome in pediatrics (2012) Endocrinol Metab Clin North Am 41: 793-803.
- https://doi.org/10.1016/j.ecl.2018.02.008
- Beauregard C,
Dickstein G and Lacroix A. Classic and recent etiologies of Cushing’s syndrome:
diagnosis and therapy (2002) Treat Endocrinol 1: 79-94.
- https://doi.org/10.2165/00024677-200201020-00002
- Nishioka H and
Yamada S. Cushing’s Disease (2019) J Clin Med 12: 1-11 https://doi.org/10.3390/jcm8111951
- Tsigos C and Chrousos
GP. Differential diagnosis and management of Cushing’s syndrome (1996) Annu Rev
Med 47: 443-61. https://doi.org/10.1146/annurev.med.47.1.443
- Invitti C, Pecori
Giraldi F, de Martin M and Cavagnini F. Diagnosis and management of Cushing’s
syndrome: results of an Italian multicentre study. Study Group of the Italian
Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal
Axis (1999) J Clin Endocrinol Metab 84: 440-448. https://doi.org/10.1210/jcem.84.2.5465
- Penezić Z, Zarković
M, Vujović S and Drezgić M. Diagnosis and differential diagnosis of Cushing’s
syndrome (2006) Srp Arh Celok Lek 134: 558-566.
- Nieman LK and Ilias
I. Evaluation and treatment of Cushing’s syndrome (2005) Am J Med 118:1340-1346.
https://doi.org/10.1016/j.amjmed.2005.01.059
- Nierenberg AA and
Feinstein AR. How to evaluate a diagnostic marker test. Lessons from the rise
and fall of dexamethasone suppression test (1988) JAMA 259: 1699-1702.
- Fassnacht M, Arlt
W, Bancos I, Dralle H, Newell-Price J, et al. Management of adrenal
incidentalomas: European Society of Endocrinology Clinical Practice Guideline
in collaboration with the European Network for the Study of Adrenal Tumors
(2016) Eur J Endocrinol 175: 1-34. https://doi.org/10.1530/EJE-16-0467
- Wolthers OD,
Mersmann S and Dissanayake S. A Pilot Study of the Normative Range of Overnight
Urinary Free Cortisol Corrected for Creatinine in Children (2018) Clin Drug
Investig. 38: 313-318. https://doi.org/10.1007/s40261-017-0609-x
- Valassi E, Franz H,
Brue T, Feelders RA, Netea-Maier R, et al. Diagnostic tests for Cushing’s
syndrome differ from published guidelines: data from ERCUSYN (2017) Eur J
Endocrinol 176: 613-624. https://doi.org/10.1530/EJE-16-0967
- Ezzat S, Asa SL,
Couldwell WT, Barr CE, Dodge WE, et al. The prevalence of pituitary adenomas: a
systematic review (2004) Cancer 101: 613-619. https://doi.org/10.1002/cncr.20412
- Hirsch D, Shimon I,
Manisterski Y, Aviran-Barak N, Amitai O, et al. Cushing’s syndrome: comparison
between Cushing’s disease and adrenal Cushing’s (2008) Endocrine 62: 712-720. https://doi.org/10.1007/s12020-018-1709-y
- El-Farhan N, Rees
DA and Evans C. Measuring cortisol in serum, urine and saliva -are our assays
good enough? (2017) Ann Clin Biochem 54: 308-322. https://doi.org/10.1177/0004563216687335
- Pecori GF. Recent
challenges in the diagnosis of Cushing’s syndrome (2009) Horm Res 71: 123-127.
https://doi.org/10.1159/000178053
- Raff H and Findling
JW. A physiologic approach to diagnosis of the Cushing syndrome (2003) Ann
Intern Med 138: 980–991. https://doi.org/10.7326/0003-4819-138-12-200306170-00010
- Law M, Wang R, Liu
C-SJ, Shiroishi MS, Carmichael JD, et al. Value of pituitary gland MRI at 7 T
in Cushing’s disease and relationship to inferior petrosal sinus sampling: case
report (2018) J Neurosurg 1: 1-5. https://doi.org/10.3171/2017.9.JNS171969
- Wiggam MI, Heaney
AP, McIlrath EM, McCance DR, Sheridan B, et al. Bilateral inferior petrosal
sinus sampling in the differential diagnosis of adrenocorticotropin-dependent
Cushing’s syndrome: a comparison with other diagnostic tests (2000) J Clin
Endocrinol Metab 85: 1525-1532. https://doi.org/10.1210/jcem.85.4.6574
- Quiñones-Hinojosa
A, Schmidek HH, Sweet WH. Schmidek and Sweet’s Operative neurosurgical
techniques: indications, methods, and results. Philadelphia, Pa.; London:
Saunders; 2012.
- Braun LT, Riester
A, Oßwald-Kopp A, Fazel J, Rubinstein G, et al. Toward a Diagnostic Score in
Cushing’s Syndrome (2019) Front Endocrinol 10: 766.
- https://doi.org/10.3389/fendo.2019.00766
- Nelson DH, Meakin
JW and Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for
Cushing’s syndrome (1960) Ann Intern Med 52: 560-569. https://doi.org/10.7326/0003-4819-52-3-560
- Friedman TC, Ghods
DE, Shahinian HK, Zachery L, Shayesteh N, et al. High Prevalence of Normal
Tests Assessing Hypercortisolism in Subjects with Mild and Episodic Cushing’s
Syndrome Suggests that the Paradigm for Diagnosis and Exclusion of Cushing’s
Syndrome Requires Multiple Testing (2010) Horm Metab Re 42: 874-881. https://doi.org/10.1055/s-0030-1263128
- Friedman TC. An
update on the overnight dexamethasone suppression test for the diagnosis of
Cushing’s syndrome: limitations in patients with mild and/or episodic
hypercortisolism (2016) Exp Clin Endocrinol Diabetes 114: 356-360. https://doi.org/10.1055/s-2006-924281
- https://linkinghub.elsevier.com/retrieve/pii/B9780128012383994
- Odeniyi IA, Ifedayo
AO, Fasanmade OA and Olufemi AF. Urinary free cortisol in the diagnosis of
Cushing’s syndrome: how useful? (2013) Niger J Clin Pract 16: 269-272. https://doi.org/10.4103/1119-3077.113445
- Newell-Price J,
Trainer P, Perry L, Wass J, et al. Grossman A, Besser M. A single sleeping
midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome
(1995) Clin Endocrinol (Oxf) 43: 545-550. https://doi.org/10.1111/j.1365-2265.1995.tb02918.x
- Direk N, Dekker
MJHJ, Luik AI, Kirschbaum C, de Rijke YB, et al. The very low-dose
dexamethasone suppression test in the general population: a cross-sectional
study (2016) PloS One 11: e0164348. https://doi.org/10.1371/journal.pone.0164348
- Zampetti B,
Grossrubatscher E, Dalino Ciaramella P, Boccardi E and Loli P. Bilateral inferior
petrosal sinus sampling (2016) Endocr Connect 5: 12-25. https://doi.org/10.1530/EC-16-0029
- Chaudhary V and Bano
S. Imaging of the pituitary: Recent advances (2011) Indian J Endocrinol Metab 15:
S216-223. https://doi.org/10.4103/2230-8210.84871
- Wang F, Liu J,
Zhang R, Bai Y, Li C, et al. CT and MRI of adrenal gland pathologies (2018)
Quant Imaging Med Surg 8: 853-875. https://doi.org/10.21037/qims.2018.09.13
- Lee HB, Kim ST, Kim
H-J, Kim KH, Jeon P, et al. Usefulness of the dynamic gadolinium-enhanced
magnetic resonance imaging with simultaneous acquisition of coronal and
sagittal planes for detection of pituitary micro adenomas (2012) Eur Radiol 22:
514-518. https://doi.org/10.1007/s00330-011-2291-3
- Gogas JG, Skalkeas GD, Sechas MN, Skandalakis PN. Scanning of the adrenals in Cushing’s syndrome (1987) Am Surg 53: 472-475.
- Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors (2016) Eur J Endocrinol 175: 1–34. https://doi.org/10.1530/EJE-16-0467
*Corresponding author:
Tofail Ahmed, Department of Endocrinology, BIRDEM, Diabetic Association of Bangladesh, Bangladesh, Email: tofail.ahmed@yahoo.com
Citation:
Ahmed T, Mahtab H, Tofail T, Morshed AHG,
Rahman BR and Khan AS. Current status of low dose overnight dexamethasone
supression test (LODST) (2020) J Obesity and Diabetes 4: 5-8.
Keywords
Low dose Overnight Dexamethasone Suppression Test,
Cushing’s syndrome, Cushing’s disease, Cortisol and detection rate of CS.
Abbreviations: LODST-Low
dose Overnight Dexamethasone Suppression Test, CS-Cushing’s
syndrome,
CD-Cushing’s
disease, DMRI-Dynamic
Contrast-Enhanced MRI, BIRDEM- Bangladesh Institute for Research and Rehabilitation
in Diabetes, Endocrine and Metabolic Disorders.